(Q36662842)

15 August 2017

1 reference

reason for preferred rank

title

Clinical Use of Biologic Response Modifiers in Cancer Treatment: An Overview Part II. Colony-Stimulating Factors and Interleukin-2 (English)

1 reference

https://api.crossref.org/works/10.1177/106002809102500509

5 November 2022

Clinical use of biologic response modifiers in cancer treatment: an overview. Part II. Colony-stimulating factors and interleukin-2 (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1712521

5 November 2022

author name string

C. M. Balmer

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1712521

5 November 2022

language of work or name

English

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=1712521

5 November 2022

publication date

1 May 1991

1 reference

full work available at URL

15 August 2017

http://journals.sagepub.com/doi/pdf/10.1177/106002809102500509

1 reference

https://api.crossref.org/works/10.1177/106002809102500509

DICP : the annals of pharmacotherapy

5 November 2022

published in

1 reference

15 August 2017

volume

25

1 reference

15 August 2017

issue

5

1 reference

15 August 2017

page(s)

490-498

1 reference

The granulocyte-macrophage colony-stimulating factors

15 August 2017

cites work

1

1 reference

https://api.crossref.org/works/10.1177/106002809102500509

Hormones that stimulate the growth of blood cells.

5 November 2022

2

1 reference

https://api.crossref.org/works/10.1177/106002809102500509

Colony-stimulating factors and host defense

5 November 2022

3

1 reference

https://api.crossref.org/works/10.1177/106002809102500509

Clinical use of recombinant human hematopoietic growth factors

5 November 2022

4

1 reference

https://api.crossref.org/works/10.1177/106002809102500509

Hematopoietic growth factors. Biology and clinical applications

5 November 2022

5

1 reference

https://api.crossref.org/works/10.1177/106002809102500509

Effects of bacterially synthesized recombinant human granulocyte-macrophage colony-stimulating factor in patients with advanced malignancy

5 November 2022

7

1 reference

https://api.crossref.org/works/10.1177/106002809102500509

Effect of granulocyte colony stimulating factor on neutropenia induced by cytotoxic chemotherapy

5 November 2022

9

1 reference

https://api.crossref.org/works/10.1177/106002809102500509

Controversies in the management of febrile neutropenic cancer patients

5 November 2022

10

1 reference

https://api.crossref.org/works/10.1177/106002809102500509

Effect of recombinant human granulocyte-macrophage colony-stimulating factor on chemotherapy-induced myelosuppression

5 November 2022

11

1 reference

https://api.crossref.org/works/10.1177/106002809102500509

Effect of granulocyte colony-stimulating factor on neutropenia and associated morbidity due to chemotherapy for transitional-cell carcinoma of the urothelium

5 November 2022

12

1 reference

https://api.crossref.org/works/10.1177/106002809102500509

Phase I/II study of recombinant human granulocyte colony-stimulating factor in patients receiving intensive chemotherapy for small cell lung cancer

5 November 2022

13

1 reference

https://api.crossref.org/works/10.1177/106002809102500509

Recombinant human granulocyte colony-stimulating factor hastens granulocyte recovery after high-dose chemotherapy and autologous bone marrow transplantation in Hodgkin's disease

5 November 2022

17

1 reference

https://api.crossref.org/works/10.1177/106002809102500509

Effect of Recombinant Human Granulocyte-Macrophage Colony-Stimulating Factor on Hematopoietic Reconstitution after High-Dose Chemotherapy and Autologous Bone Marrow Transplantation

5 November 2022

18

1 reference

https://api.crossref.org/works/10.1177/106002809102500509

Effects of recombinant human granulocyte-macrophage colony-stimulating factor in patients with myelodysplastic syndromes

5 November 2022

22

1 reference

https://api.crossref.org/works/10.1177/106002809102500509

Treatment of myelodysplastic syndromes with recombinant human granulocyte colony-stimulating factor. A phase I-II trial

5 November 2022

23

1 reference

https://api.crossref.org/works/10.1177/106002809102500509

Subcutaneous granulocyte-macrophage colony-stimulating factor in patients with myelodysplastic syndrome: toxicity, pharmacokinetics, and hematological effects

5 November 2022

24

1 reference

https://api.crossref.org/works/10.1177/106002809102500509

Therapy for neutropenia in hairy cell leukemia with recombinant human granulocyte colony-stimulating factor

5 November 2022

26

1 reference

https://api.crossref.org/works/10.1177/106002809102500509

Effects of recombinant human granulocyte colony-stimulating factor on neutropenia in patients with congenital agranulocytosis

5 November 2022

27

1 reference

https://api.crossref.org/works/10.1177/106002809102500509

Effect of recombinant human granulocyte-macrophage colony-stimulating factor on myelopoiesis in the acquired immunodeficiency syndrome

5 November 2022

28

1 reference

https://api.crossref.org/works/10.1177/106002809102500509

Hematopoietic responses in patients with advanced malignancy treated with recombinant human granulocyte-macrophage colony-stimulating factor

5 November 2022

31

1 reference

https://api.crossref.org/works/10.1177/106002809102500509

Amelioration of chemotherapy-induced thrombocytopenia by GM-CSF: apparent dose and schedule dependency

5 November 2022

32

1 reference

https://api.crossref.org/works/10.1177/106002809102500509

Adoptive Immunotherapy of Established Pulmonary Metastases with LAK Cells and Recombinant Interleukin-2

5 November 2022

35

1 reference

https://api.crossref.org/works/10.1177/106002809102500509

Phase I evaluation of recombinant interleukin-2 in patients with advanced malignant disease

5 November 2022

38

1 reference

https://api.crossref.org/works/10.1177/106002809102500509

Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer

5 November 2022

40

1 reference

https://api.crossref.org/works/10.1177/106002809102500509

A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone

5 November 2022

42

1 reference

https://api.crossref.org/works/10.1177/106002809102500509

Constant-infusion recombinant interleukin-2 in adoptive immunotherapy of advanced cancer

5 November 2022

43

1 reference

https://api.crossref.org/works/10.1177/106002809102500509

A new regimen of interleukin 2 and lymphokine-activated killer cells. Efficacy without significant toxicity

5 November 2022

44

1 reference

https://api.crossref.org/works/10.1177/106002809102500509

Recombinant interleukin-2 by continuous infusion and adoptive transfer of recombinant interleukin-2-activated cells in patients with advanced cancer

5 November 2022

46

1 reference

https://api.crossref.org/works/10.1177/106002809102500509

Phase II trial of outpatient interleukin-2 in malignant lymphoma, chronic lymphocytic leukemia, and selected solid tumors

5 November 2022

47

1 reference

https://api.crossref.org/works/10.1177/106002809102500509

A phase I clinical trial of recombinant interleukin-2 by periodic 24-hour intravenous infusions

5 November 2022

48

1 reference

https://api.crossref.org/works/10.1177/106002809102500509

Phase I study of weekly 24-hour infusions of recombinant human interleukin-2.

5 November 2022

49

1 reference

https://api.crossref.org/works/10.1177/106002809102500509

Phase II trial of high-dose intermittent interleukin-2 in metastatic renal cell carcinoma: a Southwest Oncology Group study

5 November 2022

51

1 reference

https://api.crossref.org/works/10.1177/106002809102500509

Repetitive weekly cycles of recombinant human interleukin-2: responses of renal carcinoma with acceptable toxicity

5 November 2022

52

1 reference

https://api.crossref.org/works/10.1177/106002809102500509

Effectiveness and tolerability of low-dose cyclophosphamide and low-dose intravenous interleukin-2 in disseminated melanoma [corrected].

5 November 2022

59

1 reference

https://api.crossref.org/works/10.1177/106002809102500509

Combination therapy with interleukin-2 and alpha-interferon for the treatment of patients with advanced cancer

5 November 2022

63

1 reference

https://api.crossref.org/works/10.1177/106002809102500509

Concomitant administration of recombinant human interleukin-2 and recombinant interferon alpha-2A in cancer patients: a phase I study

5 November 2022

64

1 reference

https://api.crossref.org/works/10.1177/106002809102500509

Cardiorespiratory effects of immunotherapy with interleukin-2.

5 November 2022

67

1 reference

https://api.crossref.org/works/10.1177/106002809102500509

Myocardial toxic effects during recombinant interleukin-2 therapy

5 November 2022

68

1 reference

https://api.crossref.org/works/10.1177/106002809102500509

The hemodynamic effects of treatment with interleukin-2 and lymphokine-activated killer cells

5 November 2022

69

1 reference

https://api.crossref.org/works/10.1177/106002809102500509

Increased vascular permeability in organs mediated by the systemic administration of lymphokine-activated killer cells and recombinant interleukin-2 in mice

5 November 2022

70

1 reference

https://api.crossref.org/works/10.1177/106002809102500509

Effects of interleukin-2 on renal function in patients receiving immunotherapy for advanced cancer

5 November 2022

71

1 reference

https://api.crossref.org/works/10.1177/106002809102500509

Effects of interleukin-2 immunotherapy on renal function

5 November 2022

72

1 reference

https://api.crossref.org/works/10.1177/106002809102500509

Interleukin-2 induces profound reversible cholestasis: a detailed analysis in treated cancer patients.

5 November 2022

74

1 reference

https://api.crossref.org/works/10.1177/106002809102500509

The neuropsychiatric effects of treatment with interleukin-2 and lymphokine-activated killer cells.

5 November 2022

76

1 reference

https://api.crossref.org/works/10.1177/106002809102500509

Hypothyroidism after treatment with interleukin-2 and lymphokine-activated killer cells

5 November 2022

77

1 reference

https://api.crossref.org/works/10.1177/106002809102500509

Marked disparity in incidence of bacterial infections in patients with the acquired immunodeficiency syndrome receiving interleukin-2 or interferon-gamma

5 November 2022

78

1 reference

https://api.crossref.org/works/10.1177/106002809102500509

Reduction of toxicity of interleukin-2 and lymphokine-activated killer cells in humans by the administration of corticosteroids

5 November 2022

80

1 reference

https://api.crossref.org/works/10.1177/106002809102500509

Influence of dose and duration of infusion of interleukin-2 on toxicity and immunomodulation

5 November 2022

82

1 reference

https://api.crossref.org/works/10.1177/106002809102500509

A new approach to the adoptive immunotherapy of cancer with tumor-infiltrating lymphocytes

5 November 2022

85

1 reference

https://api.crossref.org/works/10.1177/106002809102500509

Immunotherapy of patients with advanced cancer using tumor-infiltrating lymphocytes and recombinant interleukin-2: a pilot study

5 November 2022

86

1 reference

https://api.crossref.org/works/10.1177/106002809102500509

Gene transfer into humans--immunotherapy of patients with advanced melanoma, using tumor-infiltrating lymphocytes modified by retroviral gene transduction

5 November 2022

87

1 reference

https://api.crossref.org/works/10.1177/106002809102500509

5 November 2022

Identifiers

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=1712521

5 November 2022

1 reference